MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Trevena Company Profile (NASDAQ:TRVN)

Consensus Ratings for Trevena (NASDAQ:TRVN) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.22 (138.22% upside)

Analysts' Ratings History for Trevena (NASDAQ:TRVN)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016WedbushReiterated RatingOutperform$20.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Needham & Company LLCReiterated RatingBuy$14.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016FBR & Co.Boost Price TargetOutperform$13.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016WallachBeth CapitalInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Jefferies GroupReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Trevena (NASDAQ:TRVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/5/2016Q1($0.32)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.34)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.37)($0.28)$1.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.33)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.36)($0.59)$0.03 million$0.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Trevena (NASDAQ:TRVN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.33)($0.24)($0.29)
Q2 20165($0.38)($0.27)($0.33)
Q3 20164($0.39)$0.44($0.14)
Q4 20165($0.47)($0.26)($0.33)
Q1 20171($0.53)($0.53)($0.53)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.52)($0.52)($0.52)
Q4 20171($0.57)($0.57)($0.57)
(Data provided by Zacks Investment Research)
Dividend History for Trevena (NASDAQ:TRVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Trevena (NASDAQ:TRVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015David SoergelCMOSell27,217$10.55$287,139.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Trevena (NASDAQ:TRVN)
DateHeadline
06/24/16 09:28 AMTrevena, Inc. (NASDAQ:TRVN) Surged 8.86% Afterhours: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ... - KC Register
06/23/16 07:40 PMTrevena, Inc. (NASDAQ:TRVN) Stock Momentum Hits EXTREME Weakness - CML News
06/22/16 08:00 AMBiotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
06/22/16 08:00 AMAnthera Pharmaceuticals : Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
06/16/16 03:49 PM6/16/16 - Trevena to Present at the JMP Life Sciences Conference - [at noodls] - Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief ...
06/16/16 03:01 PMTrevena to Present at the JMP Life Sciences Conference - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief medical officer, David Soergel, M.D., will present a company overview at the JMP Life Sciences Conference on June 21st at 2:00p.m.
06/09/16 07:27 PMTrevena Inc (NASDAQ:TRVN) Just Got Its Billion Dollar Pain Management Bid Underway - Market Exclusive
06/09/16 10:00 AMTrevena Inc (TRVN) Just Got Its Billion Dollar Pain Management Bid Underway - Insider Monkey (blog)
06/09/16 09:34 AMTrevena Inc (TRVN) Just Got Its Billion Dollar Pain Management Bid Underway -
06/08/16 11:15 AMKing of Prussia firm begins late-stage testing of new type of pain medicine -
06/08/16 10:02 AMTrevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of ... - Business Wire (press release)
06/08/16 08:18 AM6/8/16 - Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain - [at noodls] - - Trials include comparisons of efficacy, safety and tolerability of oliceridine to both placebo and morphine - - Top-line data for both studies expected in 1Q 2017 - Trevena, Inc. (NASDAQ: TRVN), a clinical ...
06/08/16 06:00 AMTrevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced the enrollment of the first patients in the Phase 3 APOLLO-1 and APOLLO-2 studies of oliceridine in patients suffering moderate to severe acute pain following bunionectomy and abdominoplasty, respectively.
06/05/16 09:36 AMPortfolio Of Healthcare Movers: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , Trevena, Inc. (NASDAQ:TRVN) - Is stories
06/03/16 07:38 PMCowen and Company Reiterates Buy Rating for Trevena Inc (TRVN) - Let Me Know About This
06/02/16 07:10 AMTrevena, Inc. breached its 50 day moving average in a Bullish Manner : TRVN-US : June 2, 2016 -
06/01/16 03:01 PMTrevena to Present at the Jefferies 2016 Healthcare Conference - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m.
06/01/16 09:54 AMTrevena Inc (TRVN) Receives Buy Rating from FBR & Co. - Let Me Know About This - Trevena Inc (TRVN) Receives Buy Rating from FBR & Co.Let Me Know About ThisTrevena logo Trevena Inc (NASDAQ:TRVN)'s stock had its “buy” rating reaffirmed by equities research analysts at FBR & Co. in a note issued to investors on Wednesday. They currently have a $16.00 target price on the biopharmaceutical company's stock.Trevena Inc (NASDAQ:TRVN) Analyst ReviewRisers & FallersThe President & CEO of Trevena Inc (NASDAQ: TRVN) is Buying SharesAnalyst RatingsMaxine Gowen the President & CEO of Trevena Inc (NASDAQ:TRVN), Made a Purchase of 22084 Shares of the ...HNNFinance Dailyall 5 news articles »
05/31/16 07:19 PMShare Rating Focus on Trevena, Inc. (NASDAQ:TRVN) - HNN - Share Rating Focus on Trevena, Inc. (NASDAQ:TRVN)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.13 on shares of Trevena, Inc. (NASDAQ:TRVN). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
05/31/16 07:19 PMMaxine Gowen the President & CEO of Trevena Inc (NASDAQ:TRVN), Made a Purchase of 22084 Shares of the ... - HNN - Maxine Gowen the President & CEO of Trevena Inc (NASDAQ:TRVN), Made a Purchase of 22084 Shares of the ...HNNA few days ago, an insider trading purchase was made. Maxine Gowen, the President & CEO and an insider of Trevena Inc purchased a total of 22,084 shares of Trevena Inc, worth precisely $157,275 U.S. Dollars, at $7.1 per share at the time of the purchase.Insider Activity - Trevena, Inc. (NASDAQ:TRVN)Finance Dailyall 2 news articles »
05/24/16 01:42 PMAfter Last Week What Do Analysts Think Of Trevena Inc (NASDAQ:TRVN) - Share Trading News - After Last Week What Do Analysts Think Of Trevena Inc (NASDAQ:TRVN)Share Trading News03/05/2014 – Zacks began new coverage on Trevena Inc giving the company a “hold” rating. The share price of Trevena Inc (NASDAQ:TRVN) was up +5.38% during the last trading session, with a day high of 6.91. 489074 shares were traded on Trevena Inc's ...Trevena Incorporated (NASDAQ:TRVN) Shorted Shares Decreased By 3.4%Wall Street Hints and Newsall 2 news articles »
05/24/16 01:42 PMHold Calls Count For Trevena, Inc. (NASDAQ:TRVN) At 0 - Stocks Daily - Hold Calls Count For Trevena, Inc. (NASDAQ:TRVN) At 0Stocks DailyBuy calls count on Trevena, Inc. (NASDAQ:TRVN)'s stock stands at 1 while Sell recommendations is 0. Hold recommendation is 0. Trevena, Inc. (NASDAQ:TRVN) has a total of 7 Strong Buy recommendations and 0 Strong Sell advises as of 2016-05-22.and more »
05/20/16 01:27 PMLatest Analyst Ratings For Trevena Inc (NASDAQ:TRVN) - Share Trading News - Share Trading NewsLatest Analyst Ratings For Trevena Inc (NASDAQ:TRVN)Share Trading News05/17/2016 – Trevena Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 16 price target on the stock. 03/02/2016 – WallachBeth Capital began new coverage on Trevena Inc giving the company a “buy” rating.Trevena, Inc. (NASDAQ:TRVN) Hovering Around $6.56Investor NewswireTrevena Inc (NASDAQ:TRVN) Earnings per Share overviewNews OracleAnalysts Have Conflicting Sentiments on These Healthcare Companies: Trevena Inc. (NASDAQ: TRVN), Immune ...Markets.coMarket Digest -The Postall 8 news articles »
05/20/16 01:27 PMTop News: Atlas Resource Partners, L.P. (NYSE:ARP), Trevena, Inc. (NASDAQ:TRVN), Elbit Systems Ltd. (NASDAQ ... - KC Register - Top News: Atlas Resource Partners, L.P. (NYSE:ARP), Trevena, Inc. (NASDAQ:TRVN), Elbit Systems Ltd. (NASDAQ ...KC RegisterOn 16 May, Trevena, Inc. (NASDAQ:TRVN) announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead ...and more »
05/20/16 01:27 PMRevenue Update on Trevena Inc(NASDAQ:TRVN) - Trade Calls - Revenue Update on Trevena Inc(NASDAQ:TRVN)Trade CallsTrevena Inc(NASDAQ:TRVN) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $1.88M. Analysts estimated a revenue of $1.84M. Earnings per share were ...
05/19/16 07:03 PMETF’s with exposure to Trevena, Inc. : May 20, 2016 -
05/19/16 08:06 AMTREVENA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 01:46 PMSetbacks Still Outweigh Successes In Heart Failure - Seeking Alpha - Setbacks Still Outweigh Successes In Heart FailureSeeking AlphaYesterday's failure of Trevena's (NASDAQ:TRVN) TRV027 to meet either its primary or secondary endpoints in the Phase IIb Blast-AHF study marks another disappointment for a promising project in the challenging field of heart failure. Trevena has not yet ...
05/18/16 01:46 PMTrevena, Inc. (NASDAQ:TRVN) Hovering Around $6.56 - Investor Newswire - Share Trading NewsTrevena, Inc. (NASDAQ:TRVN) Hovering Around $6.56Investor NewswireOn performing technical analysis of Trevena, Inc. (NASDAQ:TRVN) stock, it is noted that the stock is $-1.33 points away -16.28% from its fifty-day MA of $8.18. It is $-2.17 or -24.04% away $9.02, the 200-day MA (Moving Average) of stock. Also, the ...Latest Analyst Ratings For Trevena Inc (NASDAQ:TRVN)Share Trading NewsTrevena Inc (TRVN) is Reiterated by Needham to Buy, Lowers Price Target to $ 11Market DigestTrevena Incorporated (NASDAQ:TRVN) Short Interest Decreased By 3.4%The Postall 8 news articles »
05/17/16 03:25 PMTrevena, Inc. :TRVN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 01:59 PMBuy Calls Count For Trevena, Inc. (NASDAQ:TRVN) At 0 - Stocks Daily - Buy Calls Count For Trevena, Inc. (NASDAQ:TRVN) At 0Stocks DailyZacks line of rating gives scores to firms on a basic 1-5 scale. As per this rating line, a score close to the lower band of 1-2 indicates a Buy, 3 rating calls for Hold while 4 or 5 rating denotes Sell. Most of the research firms have their self ...and more »
05/17/16 01:59 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Trevena Inc. (NASDAQ: TRVN), Immune ... - Markets.co - Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevena Inc. (NASDAQ: TRVN), Immune ...Markets.coAnalysts have been eager to weigh in on the Healthcare sector with new ratings on Trevena Inc. (NASDAQ: TRVN), Immune Pharmaceuticals Inc (NASDAQ: IMNP) and OHR Pharmaceutical Inc (NASDAQ: OHRP). Trevena Inc. (NASDAQ: TRVN). Cowen & Co.
05/17/16 01:59 PMAllergan plc Ordinary Shares (NYSE:AGN) & Trevena Inc (NASDAQ:TRVN) Healthcare Investor's Watch List - Wall Street 24 - NYSE JournalAllergan plc Ordinary Shares (NYSE:AGN) & Trevena Inc (NASDAQ:TRVN) Healthcare Investor's Watch ListWall Street 24On Monday, Shares of Allergan plc Ordinary Shares (NYSE:AGN) gained 0.77% to $225.07. The share price is trading in a range of $220.10 – $228.53. The stock exchanged hands with 3.38 Million shares contrast to its average daily volume of 7.34 Million ...Frontline Active Stocks in Broker Choice: Allergan (NYSE:AGN), Range Resources Corporation (NYSE:RRC), Trevena ...Street Wise Report (press release) (blog)all 5 news articles »
05/17/16 01:59 PMEarnings Expectation Watch List: Trevena Inc (NASDAQ:TRVN) - News Oracle - News OracleEarnings Expectation Watch List: Trevena Inc (NASDAQ:TRVN)News OracleLast Trade: The Company fell -7.33% and finished at $6.32. The daily volume was measured at 3.69 million shares. The 52-week high of the share price is $13.57 and the 52-week low is $5.06. The company has a market cap of $321.26 million. Its latest ...and more »
05/17/16 01:59 PMBuzz Stocks: Anacor Pharmaceuticals Inc, Yahoo! Inc., and Trevena Inc - Schaeffers Research (blog) - Schaeffers Research (blog)Buzz Stocks: Anacor Pharmaceuticals Inc, Yahoo! Inc., and Trevena IncSchaeffers Research (blog)... Apple Inc. (AAPL) boost inspired by Warren Buffett. Among equities in focus today are biopharmaceutical company Anacor Pharmaceuticals Inc (NASDAQ:ANAC), tech stock Yahoo! Inc. (NASDAQ:YHOO), and drugmaker Trevena Inc (NASDAQ:TRVN).Pre-Market Movers: Apple Inc. (NASDAQ:AAPL), Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC), Trevena, Inc ...Benchmark MonitorMid-Morning Market Update: Markets Open Higehr; Pfizer To Acquire Anacor Pharmaceuticals For $5.2BNasdaqall 222 news articles »
05/17/16 01:59 PMBiotech Stock Picking: Trevena Inc (NASDAQ:TRVN) - The Point Review - The Point ReviewBiotech Stock Picking: Trevena Inc (NASDAQ:TRVN)The Point ReviewShare of Trevena Inc (NASDAQ:TRVN) traded on -8.20 percent below secure line at 2:25PM EDT in order to take the company's stock at the price of $6.26. At the time of writing the stock exchanged hands 3.03 million shares versus average trading capacity ...Trevena Inc (TRVN) Stock Tumbles as TRV027 Fails to Meet EndpointsBidness ETCTrevena Inc (NASDAQ:TRVN)'s Company Shares Decreased 24.89% After Low VolatilityThe PostTrevena (TRVN) Announces TRV027 Phase 2b BLAST-AHF Missed Primary, Secondary EndpointsStreetInsider.comNasdaq -Sonoran Weekly Reviewall 10 news articles »
05/16/16 03:08 PMTREVENA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/16/16 06:32 AM5/16/16 - Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure - [at noodls] - Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company's ...
05/16/16 06:00 AMTrevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company’s TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure .
05/14/16 07:20 AMPrice Fluctuations to Observe: Trevena, Inc. (NASDAQ:TRVN) , U.S. Physical Therapy, Inc. (NYSE:USPH) - Street Updates - Price Fluctuations to Observe: Trevena, Inc. (NASDAQ:TRVN) , U.S. Physical Therapy, Inc. (NYSE:USPH)Street UpdatesOn 5/12/2016, Trevena, Inc. (NASDAQ:TRVN) ended trading session lower at $7.00 with -6.60%. The company traded a volume of 744.79 thousand shares as comparison to average volume of 502.82 thousand shares. During the 52 –week period, the stock's ...and more »
05/13/16 12:04 PMTREVENA INC Financials -
05/11/16 03:30 PMTrevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society - [Business Wire] - Trevena, Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016.
05/08/16 07:02 AMAnalysts Offer Insights on Healthcare Companies: Trevena Inc. (NASDAQ: TRVN), Intersect ENT Inc (NASDAQ: XENT ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Trevena Inc. (NASDAQ: TRVN), Intersect ENT Inc (NASDAQ: XENT ...Markets.coCompanies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Trevena Inc. (NASDAQ: TRVN), Intersect ENT Inc (NASDAQ: XENT), Grifols SA (NASDAQ: GRFS) and NanoString Technologies (NASDAQ: NSTG). Trevena ...
05/06/16 07:34 AMEarnings Outlook on Trevena, Inc. (NASDAQ:TRVN) - B.O.D.Y Confidential - Earnings Outlook on Trevena, Inc. (NASDAQ:TRVN)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Trevena, Inc. (NASDAQ:TRVN)'s next earnings release which is expected to be posted on or around 2016-05-05. Sell-side research firms on Wall Street are expecting that the company will post EPS of $-0.31 for ...and more »
05/05/16 06:44 AMTrevena reports 1Q loss -
05/05/16 06:11 AM5/5/16 - Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - - Results of BLAST-AHF study of TRV027 in acute heart failure expected this month - - Oliceridine pivotal Phase 3 efficacy studies expected to begin this quarter - KING OF PRUSSIA, Pa. Trevena, Inc. (NASDAQ: ...
05/05/16 06:08 AMTREVENA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/05/16 06:00 AMTrevena Reports First Quarter 2016 Financial Results and Provides Corporate Update - [Business Wire] - Trevena, Inc. , a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors , today announced financial results for the quarter ended March 31, 2016 and provided an update regarding its ongoing clinical programs.
05/04/16 06:18 AMAverage Analyst Rating for Trevena, Inc. (NASDAQ:TRVN) - B.O.D.Y Confidential - Average Analyst Rating for Trevena, Inc. (NASDAQ:TRVN)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Trevena, Inc. (NASDAQ:TRVN) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 07:04 AMTrevena (TRVN) Completes End-of-Phase 2 Meeting with FDA, Outlines Phase 3 Program for Oliceridine - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Trevena, Inc. (NASDAQ: TRVN) today announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA).
About Trevena

Trevena logoTrevena Inc. (Trevena) is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: TRV130, a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734, a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain, and TRV027, a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R), inhibiting G protein signaling and activating b-arrestin signaling. The Company has also identified a new product candidate, TRV250, a small molecule G protein biased ligand of the delta-opioid receptor program focused on central nervous system (CNS).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TRVN
  • CUSIP:
Key Metrics:
  • Previous Close: $6.39
  • 50 Day Moving Average: $6.98
  • 200 Day Moving Average: $8.16
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $333.39M
  • Current Quarter EPS Consensus Estimate: $-1.29 EPS
Additional Links:
Trevena (NASDAQ:TRVN) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha